

Review

# Fetal growth acceleration – current approach to the big baby issue

Jan Modzelewski<sup>1\*</sup>, Anna Kajdy<sup>1</sup>, Katarzyna Muzyka-Placzyńska<sup>1</sup>, Dorota Sys<sup>1</sup> and Michał Rabijewski <sup>1,\*</sup>

<sup>1</sup> Department of Reproductive Health, Centre of Postgraduate Medical Education, Warsaw, Poland; JM: jmodzelewski@cmkp.edu.pl; AK: akajdy@cmkp.edu.pl; KMP: katarzyna.muzyka-placzynska@cmkp.edu.pl; DS: dsys@cmkp.edu.pl; MR: mirab@cmkp.edu.pl

\* Correspondence: jmodzelewski@cmkp.edu.pl; Tel.: +48 22 255 99 17

**Abstract:** *Background:* Fetal overgrowth is related to many perinatal complications including stillbirth, cesarean section, maternal and neonatal injuries, and shoulder dystocia. It is related to maternal diabetes, obesity, and gestational weight gain, but also happens in low-risk pregnancies. There is ongoing discussion regarding definitions, methods of detection, and classification. The method used for detection is of crucial importance as it draws a line between those at risk and low-risk populations. *Methods:* In this a narrative review of relevant evidence identified through PubMed search with one of the general terms (macrosomia, large-for-gestational-age) combined with the outcome of interest. *Results:* This review summarizes evidence on the relation of fetal overgrowth with stillbirth, cesarean sections, shoulder dystocia, anal sphincter injury, and hemorrhage. Customized growth charts help to detect mothers and fetuses at risk of those complications. Relations between fetal overgrowth and diabetes, maternal weight, and gestational weight gain. *Conclusions:* a substantial proportion of complications are an effect of the fetus growing above its potential and should be recognized as a new dangerous condition of Fetal Growth Acceleration

**Keywords:** Diabetes, Gestational; Diagnostic Techniques, Obstetrical and Gynecological; Fetal growth acceleration; Fetal Macrosomia; Large-for-gestational-age; Obstetrics; Pregnancy Complications; Stillbirth

## 1. Introduction

Complications of pregnancy have a long-term effect on both mother and baby, therefore women and fetus health are important public health issues. Fetal growth is a clinical proxy for fetal wellbeing. While one should expect that both ends of the growth spectrum have some kind of underlying pathology, only small for gestational age and fetal growth restriction has an established definition [1]. The other end of the spectrum, being too large does not have a unified definition. Macrosomia is usually defined as an overgrowth of a fetus beyond a fixed cut-off value, while large-for-gestational age is usually defined as being larger than the 90<sup>th</sup> centile. The most commonly cited macrosomia values are between 4000 and 4500g [2]. On the other hand, neither of those definitions reflect the aspect of growth velocity. If the smaller growth spectrum is defined as fetal growth restriction (FGR), could we talk about fetal growth acceleration (FGA)? The latest definition of FGR includes the crossing of centiles in the late third trimester, could this be the case in overgrowth as well. Secondly, could this be a potential risk factor for abnormal perinatal outcome.

This review aims to summarize evidence on the consequences of fetal overgrowth, its relation with diabetes, and to propose a novel approach to the big baby issue.

## 2. Material and methods

This is a narrative review. Articles relevant to this review were identified through PubMed search with one of the general terms (macrosomia, large-for-gestational-age)

combined with the outcome of interest. Systematic reviews, meta-analyses, and large-scale register or cohort studies were included. Languages were restricted to English or Polish, no time restriction has been made, but due to possible practice changes, newer publications on the same topic were preferred over those older.

All results retrieved by search where title or title/abstract scanned. 65 full text was read and 41 relevant included. Fact that the study supported or not a hypothesis of this review where did not affect the decision to include the study.

### 3. Results

#### 3.1 Diabetes, prepregnancy weight, and gestational weight gain – risk factors for fetal overgrowth.

There are several risk factors of extensive fetal growth including diabetes, both prepregnancy and gestational, maternal prepregnancy weight, and gestational weight gain.

Gestational diabetes mellitus (GDM) is defined as diabetes first diagnosed during pregnancy. Pregnancy physiologically results in higher insulin resistance. In women with GDM, this process is pronounced by pathological changes in both mother and placenta. One of them is the dysfunction of  $\beta$ -cells and higher maternal insulin resistance in pregnancy. Mothers glucose transporter 4 (GLUT4) signaling becomes altered without changing receptor density. As a result, maternal glucose uptake is reduced to 54% compared to normal pregnancy. In contrast, placental glucose uptake is increased [3]. As a result, the fetus produces more insulin and insulin-related growth factor-1, both potent anabolic substances, leading to fetal overgrowth [4].

Pre-pregnancy diabetes, both type 1 and type 2 have an even greater impact on fetal growth than gestational diabetes. Maternal hyperglycemia causes excessive glucose transport to the placenta, fetal hyperinsulinemia, and excess insulin growth factor-1 secretion. Glucose variability has a stronger effect on fetal growth than basal glycemic levels reflected by HbA1c levels. On the other hand, studies on optimal glycemic control showed a reduction in fetal overgrowth, but despite that fetal growth was altered. Other studies showed a relation between amino acid levels and advanced maternal age, leptin, fatty acids, especially triglycerides, and fetal overgrowth [5]. Surprisingly, despite poorer metabolic control reflected by HbA1c levels, women with type 1 diabetes have better outcomes in terms of perinatal mortality and congenital malformations than women with type 2 diabetes [6].

Gestational weight gain and pre-pregnancy BMI both impact fetal growth. A large metaanalysis of individual patient data showed that the risk of having an LGA neonate grows substantially in women with higher pregestational BMI and in those who had excessive weight gain in pregnancy [7]. Both factors affect fetal growth independently and have an additive effect. Similar results were observed in other recent studies [8,9].

Macrosomia has consequences for both mother and child. Most of all excess fetal weight leads to an increased risk of hypoxia, postpartum hemorrhage (PPH), cesarean section, or instrumental delivery. Shoulder dystocia occurs more often, leading to fractures, brachial plexus injury, and obstetric anal sphincter injury (OASIS). [10,11].

Different factors involved in fetal overgrowth trigger specific growth patterns in the fetus. Children of diabetic mothers have more adipose tissue, lower fat-free body mass, and altered anthropometric measurements, especially higher fat deposition in the upper half of the body[12]. Higher bisacromial diameter was found in children of diabetic mothers and has been confirmed as a risk factor of shoulder dystocia[13].

#### 3.2 Detection of fetal overgrowth

It is important to know the differences between the charts used to assess fetal growth. Descriptive reference curves describe growth in the given population and time. They are usually made in a retrospective manner and rarely have high methodological quality. Prescriptive standard curves show the growth of fetuses in optimal conditions, excluding any condition that could have an impact on fetal growth. Prescriptive standard curves are usually made prospectively and have higher methodological quality. Some prescriptive standards are made internationally on large and diverse populations. On the contrary,

customized standards are an attempt to describe fetal growth on the individual level, taking ethnicity, parity, maternal weight and height, and fetal sex into account [14,15]. There is an ongoing discussion in the literature on which growth charts should be used. Choosing one chart over other changes LGA rates, reclassifies some of the fetuses, and therefore changes the association of LGA with pregnancy complications [16].

Our group has proven that SGA detection is a key to success and it is probable that the same applies to LGA [17]. Different strategies were applied to optimize LGA detection. A comparison of serial scans and growth velocity with single measurements done by several groups shows that single measurement performed better in terms of sensitivity, especially if made close to delivery [18,19]. On the other hand, analysis of growth velocity between first and second-trimester ultrasound scans could help in the prediction of most severe cases of LGA >97th centile and macrosomia. According to a paper by Simic *et al.*, if growth acceleration equals or exceeds 7 days of ultrasound estimated gestational age between first (11-14 weeks) and early second (18-20 weeks) scans, aOR for LGA and macrosomia was 2,27 (95% CI 1,49-3,45)[20]. Strategies to predict macrosomia using contemporary used or novel biomarkers and substances are being developed, with no strategy being superior to others [19,21-25].

### 3.3 Complications

#### 3.3.1 Stillbirth

Whether accelerated fetal growth is associated with stillbirth is a matter of controversy. In a study by Wood and Tang based on a Canadian birth registry of 696 461 births including 3275 stillbirths, no relationship was found between LGA and stillbirth. [26] Authors used the Canadian population, US population, and ultrasound growth norms finding no relationship between norms used and outcome.

Mecacci *et al.* conducted a case-control trial of stillbirth in two Italian tertiary care centers. 175 stillbirth cases and 586 controls were analyzed using customized norms. Results showed a U-shaped stillbirth risk curve with the highest risk of stillbirth in the lowest and highest weight centiles. LGA >90<sup>th</sup> centile was associated with a 1,99 increase in stillbirth risk. [27]

A case-control study conducted by Bukowski *et al.* evaluated 527 stillbirths and 1821 matched controls from 5 US geographic areas using population, ultrasound, and customized standards. They found that LGA is strongly associated with stillbirth when evaluated using ultrasound (aOR 3,71) and customized norms (aOR 2,57), but not by population norms[28].

Another comparison of different growth charts and risk of perinatal complications including perinatal mortality was made by Sjaarda *et al.* showing that LGA increases the risk of stillbirth regardless of growth chart used, but custom methods had higher PPV and but lower sensitivity, in the clinical setting using customized standard would miss more cases of LGA stillbirths, but those identified would be those in fact in danger [29].

Comparison between global Intergrowth-21<sup>st</sup> [30] and customized growth chart made by Francis *et al.* showed an increased risk of stillbirth in a small-for-gestational-age group when using a customized growth chart. Results for LGA showed that using Intergrowth-21<sup>st</sup> growth chart LGA is a protective factor for stillbirth and a risk factor when using customized growth charts, but results were not statistically significant[31].

Study comparing usage of population and partially customized (using parity, fetal sex, maternal weight, and height) growth charts on data collected from Scottish medical databases by Iliodromiti *et al.*, included 979,912 term pregnancies from 1992-2010 and showed that LGA neonates by customized growth charts had a higher risk of stillbirth (aOR 1,29; LGA birthweight >90<sup>th</sup> centile; aOR 1,25 LGA birthweight >85<sup>th</sup> centile). This effect was not visible when using population growth charts [32].

Risk factors of stillbirth related to macrosomia were studied by Tam Giao Cung *et al.* Researchers analyzed all births from a major hospital in Nablus, Palestine. The cohort consisted of 5644 births and 5782 babies and included 41 stillbirths. Macrosomia was defined as weight 4500 g and above. Adjusted OR for stillbirth in macrosomia was aOR 6,3 comparing to reference birthweight of 2500-4499 g [33].

In a recent study by Salihu *et al.* authors analyzed national registers of 111 166 370 terms from 1987-2017. Macrosomia was defined as weight >4000 g and further divided into subgroups of grade one - 4000-4499g, grade 2 -4500-4999 g, and grade 3 - >5000 g. The authors observed a substantial fall in stillbirth rates during the study period in both macrosomic and normal weight fetuses. Grade 1 macrosomia was not a stillbirth risk factor (0,95 stillbirths per 1000 pregnancies), while grade 2 macrosomia increased the risk 2 fold (2,43/1000) and grade 3 had a stillbirth rate (13,03/1000) – similar to that of low birthweight fetuses (15,54/1000)[34].

Some authors suggest that macrosomia cut-off should be race-specific, which brings some analogy to growth chart customization. Research of linked US datasets of birth and infant Death (30,831,694 live births and 38,053 stillbirths) by Ye *et al.* showed that the optimal cut-off for Caucasians is 4500 g but Black and Hispanic should be lower by 200 g. Cut-off points of 4500 g and 4300 g were chosen because the indicated OR for perinatal mortality reached a pre-defined value of 2,0. Other races were not analyzed as they were not represented in sufficient numbers. The authors made adjustments for pregnancy complications including diabetes in their analysis [35].

Similar results indicating that both macrosomia and LGA or is a risk factor of stillbirth was reported by Agbozo *et al.* (aOR 2,4; macrosomia >4000g)[36], Contag *et al.* [37](HR 2,2; LGA EFW >95<sup>th</sup> centile), Lavin *et al* [38] (RR 3,4-6,6; EFW >90<sup>th</sup> centile) and Moraitis *et al.* [39] (OR 2,2; EFW >98<sup>th</sup> centile). All LGA study groups were defined using population growth charts.

### 3.3.2 Shoulder dystocia, OASIS, PPH

Shoulder dystocia may occur even if a neonate is small-for-gestational-age but the risk grows with increasing birthweight[40]. As categories of LGA by any standard and macrosomia overlap within higher birthweights it is hard to choose the best tool for the prediction of these complications.

Direct comparison of population and customized growth charts LGA and macrosomia by Larkin *et al.* showed a significant risk of shoulder dystocia, OASIS, and PPH but none was superior to others [41]. The analysis was performed on 32271 cases from a single center including 1256-2002 (depending on the method used) cases of fetal overgrowth.

In a previously mentioned paper by Sjaada *et al.* authors compared different growth charts. In an analysis of a total of 168,945 births from 12 research centers, authors used population growth charts, customized growth charts by Gardosi [42], and their model. Mothers of LGA neonates identified by customized growth charts, by either method but not population growth charts, had a greater risk of OASIS. Additionally, LGA identified by the authors' model had a greater risk of shoulder dystocia. The risk of PPH was similar in either group. LGA identified by population growth chart only had a lower risk of OASIS and shoulder dystocia than LGA identified by any customized method.

The risk of PPH in mothers of macrosomic non-LGA babies (by customized growth chart) was analyzed by Pasupathy *et al.* in 2668 cases [43]. Authors showed that mothers of neonates with birth weight >4000g but non-LGA by customized growth chart had an insignificantly higher risk of postpartum hemorrhage. On the other hand LGA with birthweight <4000 g was a risk factor of PPH (aOR 2,7 [95% CI 1,2-6,2]). The use of neither population nor customized growth charts resulted in greater RR for PPH in direct comparison.

In a study by Vieira *et al.*, researchers made a different approach to the problem of choosing the right tool for assessment of the risk of complications [44]. Based on the Swedish Medical Birth Registry a population of 212 101 term births was chosen. Using a fixed 10% false-positive rate authors found growth chart-specific cut-off points for perinatal complications including PPH, cesarean section, neonatal complications, and OASIS while achieving similar sensitivity. On the other hand, customized charts performed better in terms of perinatal mortality of LGA babies.

The rate of complications between term non-macrosomic LGA and AGA was compared by Doty *et al.* based on US birth certificates and US Vital Statistic databases. Macrosomia was defined as birthweight >4000g, LGA was assessed by population standard. Of

3 917 831 births, only 50 630 (1,3 %) was non-macrosomic LGA. Authors concluded that non-macrosomic LGA had a greater risk of combined neonatal (aOR 1,47) and maternal (aOR 1,40) morbidity including a higher risk of maternal transfusion, maternal unplanned operating room procedures, need of assisted ventilation of neonate, fetal significant birth injury, or Apgar score <5 at 5 minutes [45].

A meta-analysis comparing population and customized growth charts by Chossi *et al.* did not report that LGA neonates and mothers are at statistically significant risk of intrauterine death, admission to neonatal intensive care unit, fetal postpartum hypoglycemia, or maternal OASIS with both growth charts used. Both population and customized growth charts showed an increased risk of shoulder dystocia [46].

### 3.3.3 Cesarean section

The mode of delivery of LGA fetuses is of major concern to healthcare practitioners. The right choice of the at-risk population will result in the lowest possible rate of complications.

Different methods of customization could have different effects on intrapartum complications and the need for emergency cesarean section. In a study by Pritchard *et al.*, researchers compared the risk of the cesarean section between AGA babies and those classified as LGA by population, height only customized and height and weight customized growth charts. A total of 38 246 birth was analyzed and 1917 babies were LGA by population charts, 1754 LGA by height customization, and 1904 LGA in weight and height customization. Accordingly, 290, 263, and 413 were considered LGA by only one growth chart. Customization by height only showed the highest correlation with emergency cesarean section (OR 4,64; 95% CI 3,22–6,76) while population charts LGA did not show such correlation (OR 1,46; 95% CI 0,70-1,88) with a small difference in mean birth weight (4140 us. 4015 g). LGA height the only customization showed a better correlation with the risk of cesarean section comparing to weight-height customization charts (OR 1.85, 95% CI 1.32–2.61). When fetuses identified by only one growth chart were taken into consideration, women with LGA neonates by height only customization were at greatest risk for emergency cesarean section (OR 1.85, 95% CI 1.32–2.61). The overall rate of cesarean sections, both emergency and planned, was highest in LGA customized by height only group (61,4%) while LGA by population charts only had only 34,5%, LGA by weight-height customization only had a cesarean section rate of 41,6%, and AGA 27,3% [47].

Customized LGA by both methods showed greater OR for cesarean section than population growth charts in the study by Sjaarda *et al.* [29] but Larkin *et al.* [41] did not show any differences in cesarean section in LGA and macrosomia whatever method used.


## 4. Discussion

Not surprisingly complications of fetal overgrowth are rising with increasing fetal weight. However, complications occur even if the weight of the fetus is below the defined centile or fixed cut-off point. Evidence regarding stillbirth is confusing, but the majority of papers show that there is a link between fetal overgrowth and macrosomia. Recognition of fetal overgrowth as a risk factor of shoulder dystocia, OASIS, and PPH is well established. When it comes to cesarean section, maternal height customized fetal overgrowth diagnosis showed to be the greatest risk factor. All evidence comes from registry analysis or cohort studies, there were no randomized trials to directly evaluate methods of fetal overgrowth diagnosis. Even without any RCT available evidence described above should be considered in everyday practice and by policymakers.

Limitations of this study should be acknowledged. Firstly, the risk of bias was not assessed, including publication and reporting bias. None of the presented studies was randomized, and most were registry-based, with limitations specific to this kind of study. All identified research was included, but only one database was searched. Methodological differences between studies often make direct comparison impossible.

In our opinion, this phenomenon of fetal overgrowth needs to be recognized in a similar way that pathological smallness (FGR) and constitutional smallness (small for gestational age) are recognized [48]. Therefore we postulate to recognize Fetal Growth

Acceleration (FGA) as a new and pathological condition distinct from LGA and macrosomia. FGA fetuses grow exceeding their genetic optimal growth and what's most important exceeding placental capacity. Not all FGR have to be necessary SGA, accordingly not all FGA have to be macrosomia or LGA as shown in Figure 1. Usage of customized charts could help in the detection of those FGA cases that are missed by regular charts, but not all the cases, therefore new tools need to be developed.



**Fig. 1** Relationship between AGA – Appropriate for Gestational Age, LGA – large for gestational age, SGA – Small for Gestational Age and FGA - Fetal Growth Acceleration

## 5. Conclusions

Contemporary research shows that the method of fetal overgrowth assessment is of great importance, with emphasis on customization. Customization helps to optimize the choice of at-risk fetuses and therefore facilitates the delivery of an appropriate intervention. Probably there is a need for more than one method of customization depending on which complications are aimed to be avoided. Hopefully, fetal overgrowth is getting more attention from the scientific community promising more progress in this field soon..

**Author Contributions:** For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used “Conceptualization, JM, AK and MR.; methodology, JM, KMP, AK and DS.; software, DS.; validation JM and AK.; formal analysis, JM.; investigation, JM.; resources, JM, DS and MR.; data curation, JM and DS.; writing—original draft preparation, JM.; writing—review and editing, JM, KMP, AK, DS and MR.; visualization, DS.; supervision, MR.; project administration, DS; funding acquisition, DS and MR. All authors have read and agreed to the published version of the manuscript.” Please turn to the CRediT taxonomy for the term explanation. Authorship must be limited to those who have contributed substantially to the work reported.

**Funding:** The APC was funded by Centre of Postgraduate Medical Education, Warsaw, Poland.

**Institutional Review Board Statement:** Not applicable

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest

## References

1. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al. Consensus definition of fetal growth restriction: a Delphi procedure. *Ultrasound Obstet Gynecol* [Internet]. 2016 [cited 2019 Dec 19];48(3):333–9. Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/uog.15884>
2. Macrosomia: ACOG Practice Bulletin, Number 216. *Obstet Gynecol* [Internet]. 2020 Jan [cited 2020 Jan 2];135(1):e18. Available from: [https://journals.lww.com/greenjournal/Fulltext/2020/01000/Macrosomia\\_\\_ACOG\\_Practice\\_Bulletin,\\_Number\\_216.50.aspx](https://journals.lww.com/greenjournal/Fulltext/2020/01000/Macrosomia__ACOG_Practice_Bulletin,_Number_216.50.aspx)
3. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of Gestational Diabetes Mellitus. *Int J Mol Sci* [Internet]. 2018 Oct 26 [cited 2020 Jan 8];19(11). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274679/>
4. Catalano PM, Hauguel-De Mouzon S. Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic? *Am J Obstet Gynecol* [Internet]. 2011 Jun [cited 2020 Mar 10];204(6):479–87. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130827/>
5. McGrath RT, Glastras SJ, Hocking SL, Fulcher GR. Large-for-Gestational-Age Neonates in Type 1 Diabetes and Pregnancy: Contribution of Factors Beyond Hyperglycemia. *Diabetes Care* [Internet]. 2018 Aug 1 [cited 2020 Jan 12];41(8):1821–8. Available from: <https://care.diabetesjournals.org/content/41/8/1821>
6. Clausen TD, Mathiesen E, Ekbom P, Hellmuth E, Mandrup-Poulsen T, Damm P. Poor Pregnancy Outcome in Women With Type 2 Diabetes. *Diabetes Care* [Internet]. 2005 Feb 1 [cited 2020 Jan 12];28(2):323–8. Available from: <https://care.diabetesjournals.org/content/28/2/323>

7. Santos S, Voerman E, Amiano P, Barros H, Beilin LJ, Bergström A, et al. Impact of maternal body mass index and gestational weight gain on pregnancy complications: an individual participant data meta-analysis of European, North American and Australian cohorts. *BJOG Int J Obstet Gynaecol* [Internet]. 2019 [cited 2020 Jan 27];126(8):984–95. Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/1471-0528.15661>
8. Li C, Liu Y, Zhang W. Joint and Independent Associations of Gestational Weight Gain and Pre-Pregnancy Body Mass Index with Outcomes of Pregnancy in Chinese Women: A Retrospective Cohort Study. *PLoS ONE* [Internet]. 2015 Aug 27 [cited 2020 Jan 27];10(8). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552294/>
9. Ramonienė G, Maleckienė L, Nadišauskienė RJ, Bartusevičienė E, Railaitė DR, Mačiulevičienė R, et al. Maternal obesity and obstetric outcomes in a tertiary referral center. *Medicina (Mex)* [Internet]. 2017 Apr [cited 2021 Jan 14];53(2):109–13. Available from: <https://www.mdpi.com/1010-660X/53/2/109>
10. Turkmen S, Johansson S, Dahmoun M. Foetal Macrosomia and Foetal-Maternal Outcomes at Birth. *J Pregnancy* [Internet]. 2018 Aug 8 [cited 2019 Mar 27];2018. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106949/>
11. Beta J, Khan N, Khalil A, Fiolna M, Ramadan G, Akolekar R. Maternal and neonatal complications of fetal macrosomia: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol* [Internet]. [cited 2019 Apr 3];0(ja). Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/uog.20279>
12. McFarland MB, Trylovich CG, Langer O. Anthropometric differences in macrosomic infants of diabetic and nondiabetic mothers. *J Matern Fetal Med* [Internet]. 1998 [cited 2020 Jan 13];7(6):292–5. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291520-6661%28199811/12%297%3A6%3C292%3A%3AAID-MFM7%3E3.0.CO%3B2-A>
13. Bahar AM. Risk factors and fetal outcome in cases of shoulder dystocia compared with normal deliveries of a similar birth-weight. *BJOG Int J Obstet Gynaecol* [Internet]. 1996 [cited 2020 Jan 13];103(9):868–72. Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/j.1471-0528.1996.tb09904.x>
14. Gardosi J, Mongelli M, Wilcox M, Chang A. An adjustable fetal weight standard. *Ultrasound Obstet Gynecol* [Internet]. 1995 [cited 2019 May 21];6(3):168–74. Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1046/j.1469-0705.1995.06030168.x>
15. Salomon LJ, Alfirevic Z, Costa FDS, Deter RL, Figueras F, Ghi T, et al. ISUOG Practice Guidelines: ultrasound assessment of fetal biometry and growth. *Ultrasound Obstet Gynecol* [Internet]. 2019 [cited 2020 Mar 10];53(6):715–23. Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/uog.20272>
16. Kajdy A, Modzelewski J, Herman K, Muzyka-Placzynska K, Rabiejewski M. Growth charts and prediction of abnormal growth – what is known, what is not known and what is misunderstood. *Ginekol Pol* [Internet]. 2019 [cited 2020 Jan 13];90(12):717–21. Available from: [https://journals.viamedica.pl/ginekologia\\_polska/article/view/GP.2019.0123](https://journals.viamedica.pl/ginekologia_polska/article/view/GP.2019.0123)
17. Kajdy A, Modzelewski J, Jakubiak M, Pokropek A, Rabiejewski M. Effect of antenatal detection of small-for-gestational-age newborns in a risk stratified retrospective cohort. *Plos One*. 2019;14(10):e0224553.
18. Tarca AL, Hernandez-Andrade E, Ahn H, Garcia M, Xu Z, Korzeniewski SJ, et al. Single and Serial Fetal Biometry to Detect Preterm and Term Small- and Large-for-Gestational-Age Neonates: A Longitudinal Cohort Study. Burd I, editor. *PLOS ONE* [Internet]. 2016 Nov 1 [cited 2020 Mar 11];11(11):e0164161. Available from: <https://dx.plos.org/10.1371/journal.pone.0164161>
19. Zhang J, Kim S, Grewal J, Albert PS. Predicting large fetuses at birth: do multiple ultrasound examinations and longitudinal statistical modelling improve prediction?: Predicting macrosomia. *Paediatr Perinat Epidemiol* [Internet]. 2012 May [cited 2020 Mar 11];26(3):199–207. Available from: <http://doi.wiley.com/10.1111/j.1365-3016.2012.01261.x>
20. Simic M, Wikström A-K, Stephansson O. Accelerated fetal growth in early pregnancy and risk of severe large-for-gestational-age and macrosomic infant: a cohort study in a low-risk population. *Acta Obstet Gynecol Scand* [Internet]. 2017 [cited 2019 Dec 22];96(10):1261–8. Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/aogs.13189>
21. Migda M, Migda MS, Migda B, Wender-Ozegowska E. Maternal first trimester parameters in the prediction of excessive fetal growth in pregnant women with metabolic syndrome. *J Physiol Pharmacol Off J Pol Physiol Soc*. 2017 Dec;68(6):833–9.
22. Papastefanou I, Souka AP, Pilalis A, Eleftheriades M, Michalitsi V, Kassanos D. First trimester prediction of small- and large-for-gestation neonates by an integrated model incorporating ultrasound parameters, biochemical indices and maternal characteristics: First trimester prediction of SGA and LGA newborns. *Acta Obstet Gynecol Scand* [Internet]. 2012 Jan [cited 2020 Mar 18];91(1):104–11. Available from: <http://doi.wiley.com/10.1111/j.1600-0412.2011.01271.x>
23. Poon LCY, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH. First-Trimester Prediction of Macrosomia. *Fetal Diagn Ther* [Internet]. 2011 [cited 2020 Mar 18];29(2):139–47. Available from: <https://www.karger.com/Article/FullText/318565>
24. Rizzo G, Mappa I, Bitsadze V, Słodki M, Khizroeva J, Makatsarya A, et al. Role of first-trimester umbilical vein flow in predicting fetal macrosomia: a matched case-control study. *Ultrasound Obstet Gynecol* [Internet]. [cited 2020 Mar 18];n/a(n/a). Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/uog.20408>
25. Zbucka-Kretowska M, Kuzmicki M, Telejko B, Goscik J, Ciborowski M, Lipinska D, et al. First-trimester irisin and fetuin-A concentration in predicting macrosomia. *J Matern Fetal Neonatal Med* [Internet]. 2019 Sep 2 [cited 2020 Mar 18];32(17):2868–73. Available from: <https://doi.org/10.1080/14767058.2018.1450859>
26. Wood S, Tang S. Stillbirth and large for gestational age at birth. *J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet*. 2018 Nov 4;1–6.
27. Mecacci F, Serena C, Avagliano L, Cozzolino M, Baroni E, Rambaldi MP, et al. Stillbirths at Term: Case Control Study of Risk Factors, Growth Status and Placental Histology. *PLOS ONE* [Internet]. 2016 Dec 9 [cited 2020 Feb 4];11(12):e0166514. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0166514>

28. Bukowski R, Hansen NI, Willinger M, Reddy UM, Parker CB, Pinar H, et al. Fetal Growth and Risk of Stillbirth: A Population-Based Case-Control Study. *PLOS Med* [Internet]. 2014 Apr 22 [cited 2019 Mar 29];11(4):e1001633. Available from: <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001633>

29. Sjaarda LA, Albert PS, Mumford SL, Hinkle SN, Mendola P, Laughon SK. Customized large-for-gestational-age birthweight at term and the association with adverse perinatal outcomes. *Am J Obstet Gynecol*. 2014 Jan 1;210(1):63.e1-63.e11.

30. Villar J, Ismail LC, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *The Lancet*. 2014 Sep;384(9946):857-68.

31. Francis A, Hugh O, Gardosi J. Customized vs INTERGROWTH-21st standards for the assessment of birthweight and stillbirth risk at term. *Am J Obstet Gynecol* [Internet]. 2018 Feb 1 [cited 2019 Apr 7];218(2, Supplement):S692-9. Available from: <http://www.sciencedirect.com/science/article/pii/S0002937817324882>

32. Iliodromiti S, Mackay DF, Smith GCS, Pell JP, Sattar N, Lawlor DA, et al. Customised and Noncustomised Birth Weight Centiles and Prediction of Stillbirth and Infant Mortality and Morbidity: A Cohort Study of 979,912 Term Singleton Pregnancies in Scotland. *PLOS Med* [Internet]. 2017 Jan 31 [cited 2020 Feb 19];14(1):e1002228. Available from: <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002228>

33. Cung TG, Paus AS, Aghbar A, Kiserud T, Hinderaker SG. Stillbirths at a hospital in Nablus, 2010: a cohort study. *Glob Health Action* [Internet]. 2014 [cited 2020 Feb 6];7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157139/>

34. Salihu HM, Dongarwar D, King LM, Yusuf KK, Ibrahimi S, Salinas-Miranda AA. Phenotypes of fetal macrosomia and risk of stillbirth among term deliveries over the previous four decades. *Birth* [Internet]. [cited 2020 Mar 11];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/birt.12479>

35. Ye J, Zhang L, Chen Y, Fang F, Luo Z, Zhang J. Searching for the Definition of Macrosomia through an Outcome-Based Approach. *PLoS ONE* [Internet]. 2014 Jun 18 [cited 2019 Apr 7];9(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062533/>

36. Agbozo F, Abubakari A, Der J, Jahn A. Prevalence of low birth weight, macrosomia and stillbirth and their relationship to associated maternal risk factors in Hohoe Municipality, Ghana. *Midwifery* [Internet]. 2016 Sep [cited 2019 Mar 27];40:200-6. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0266613816301061>

37. Contag S, Brown C, Crimmins S, Goetzinger K. Influence of Birthweight on the Prospective Stillbirth Risk in the Third Trimester: A Cross-Sectional Cohort Study. *AJP Rep* [Internet]. 2016 Jul [cited 2020 Feb 5];6(3):e287. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988848/>

38. Lavin T, Pattinson RC, Nedkoff L, Gebhardt S, Preen DB. Stillbirth risk across pregnancy by size for gestational age in Western Cape Province, South Africa: Application of the fetuses-at-risk approach using perinatal audit data. *S Afr Med J* [Internet]. 2019 Nov 27 [cited 2020 Feb 16];109(12):927. Available from: <http://www.samj.org.za/index.php/samj/article/view/12776>

39. Moraitis AA, Wood AM, Fleming M, Smith GCS. Birth Weight Percentile and the Risk of Term Perinatal Death: *Obstet Gynecol* [Internet]. 2014 Aug [cited 2020 Feb 5];124(2, PART 1):274-83. Available from: <http://Insights.ovid.com/crossref?an=00006250-201408000-00011>

40. Stotland NE, Caughey AB, Breed EM, Escobar GJ. Risk factors and obstetric complications associated with macrosomia. *Int J Gynecol Obstet* [Internet]. 2004 [cited 2020 Feb 16];87(3):220-6. Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1016/j.ijgo.2004.08.010>

41. Larkin JC, Speer PD, Simhan HN. A customized standard of large size for gestational age to predict intrapartum morbidity. *Am J Obstet Gynecol* [Internet]. 2011 Jun [cited 2020 Feb 16];204(6):499.e1-499.e10. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S000293781100305X>

42. Gardosi J, Francis A. A customized standard to assess fetal growth in a US population. *Am J Obstet Gynecol* [Internet]. 2009 Jul 1 [cited 2020 Feb 16];201(1):25.e1-25.e7. Available from: <http://www.sciencedirect.com/science/article/pii/S0002937809004293>

43. Pasupathy D, McCowan LME, Poston L, Kenny LC, Dekker GA, North RA. Perinatal Outcomes in Large Infants Using Customised Birthweight Centiles and Conventional Measures of High Birthweight. *Paediatr Perinat Epidemiol* [Internet]. 2012 [cited 2019 Apr 7];26(6):543-52. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/ppe.12002>

44. Vieira MC, Relph S, Persson M, Seed PT, Pasupathy D. Determination of birth-weight centile thresholds associated with adverse perinatal outcomes using population, customised, and Intergrowth charts: A Swedish population-based cohort study. *PLOS Med* [Internet]. 2019 Sep 20 [cited 2020 Feb 17];16(9):e1002902. Available from: <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002902>

45. Doty MS, Chen H-Y, Sibai BM, Chauhan SP. Maternal and Neonatal Morbidity Associated With Early Term Delivery of Large-for-Gestational-Age But Nonmacrosomic Neonates. *Obstet Gynecol* [Internet]. 2019 Jun [cited 2020 Jan 2];133(6):1160. Available from: [https://journals.lww.com/greenjournal/fulltext/2019/06000/Maternal\\_and\\_Neonatal\\_Morbidity\\_Associated\\_With.12.aspx](https://journals.lww.com/greenjournal/fulltext/2019/06000/Maternal_and_Neonatal_Morbidity_Associated_With.12.aspx)

46. Chiossi G, Pedroza C, Costantine MM, Truong VTT, Gargano G, Saade GR. Customized vs population-based growth charts to identify neonates at risk of adverse outcome: systematic review and Bayesian meta-analysis of observational studies. *Ultrasound Obstet Gynecol* [Internet]. 2017 [cited 2019 Jun 13];50(2):156-66. Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/uog.17381>

47. Pritchard N, Lindquist A, Hiscock R, Diksha P, Walker SP, Permezel M. Customised growth charts in large-for-gestational-age infants and the association with emergency caesarean section rate. *Aust N Z J Obstet Gynaecol* [Internet]. [cited 2019 Apr 3];0(0). Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/ajo.12868>

48. Gordijn SJ, Beune IM, Ganzevoort W. Building consensus and standards in fetal growth restriction studies. *Best Pract Res Clin Obstet Gynaecol* [Internet]. 2018 May 1 [cited 2020 Mar 11];49:117–26. Available from: <http://www.sciencedirect.com/science/article/pii/S1521693418300439>